Medigene's bluebird Deal Validates TCR Technology And Immune-Oncology Strategy
Medigene's collaboration with bluebird bio is a validation of its technology platform and its new immune-oncology focused strategy.
You may also be interested in...
Bluebird has been an active deal maker as it looks to add tools, targets and technological capabilities to its R&D engine. A pair of August TCR-focused deals, including the latest with Gritstone, continue that strategy.
Looking back at the second quarter, PharmaVitae analysts have selected 10 biopharma companies with market caps under $3bn they think are primed for acquisition – and the likely candidates for a buy-out.
Also, TapImmune merger with Marker could yield T-cell therapies that address multiple tumor-associated antigens with a better safety profile than CAR-T therapy. Bluebird and Medigene expand their TCR therapy collaboration.